macular amyloidosis. Amyloidosis of skin
Conditions
Interventions
Intervention 1: intervention group: one part of lesion receives Fractional non-ablative erbium laser for 3 sessions and its energy ranges from 8 to 15 Mj/MB2. Intervention 2: control group: one part o
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Clinically confirmed macular amyloidosis macular amyloidosis lesions should be on upper back area o current skin diseases like active dermatitis, active acne, hypertrophic scars or keloids patients with Fitzpatrick skin types 2 to 4 written informed consent from patients for participation in the study and digital imaging from lesions no use of Isotretinoin during the last 3 month having no heart pacemaker no record of sensitivity to lidocaine
Exclusion criteria
Exclusion criteria: unreal expectations from treatment results macular amyloidosis lesions not being on upper back areas intolerance against laser treatment pregnancy during treatment unwillingness of patient to continue participating in the study or digital imaging from lesions Coagulopathy Patients who were under topical treatment one month before study existence of hypertrophic scars or keloids Treatment with systemic retinoid during the last 6 month other dermatologic diseases like skin infections and active lesions in the treatment area
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lesion pigmentation. Timepoint: During therapy, after each laser session and three month after last session. Method of measurement: Based on a grading system (1:low, 2:medium, 3:noticeable).;Rate of rippling. Timepoint: During therapy, after each laser session and three month after last session. Method of measurement: Based on a grading system (0:without rippling, 1:with rippling).;Intensity of lesion. Timepoint: During therapy, after each laser session and three month after last session. Method of measurement: Based on a grading system (0:without Lichenification, 1:with Lichenification).;Itching. Timepoint: During therapy, after each laser session and three month after last session. Method of measurement: Based on a grading system (0:without itching, 1:with itching). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Rozita Delghandi
Mashhad University of Medical Sciences
Outcome results
None listed